Department of Cell and Developmental Biology; Department of Neurology; Wellstone Center for FSHD
Derepression of DUX4 in skeletal muscle has emerged as a likely cause of pathology in facioscapulohumeral muscular dystrophy (FSHD). Here we report on the use of antisense phosphorodiamidate morpholino oligonucleotides to suppress DUX4 expression and function in FSHD myotubes and xenografts. The most effective was phosphorodiamidate morpholino oligonucleotide FM10, which targets the polyadenylation signal of DUX4. FM10 had no significant cell toxicity, and RNA-seq analyses of FSHD and control myotubes revealed that FM10 down-regulated many transcriptional targets of DUX4, without overt off-target effects. Electroporation of FM10 into FSHD patient muscle xenografts in mice also down-regulated DUX4 and DUX4 targets. These findings demonstrate the potential of antisense phosphorodiamidate morpholino oligonucleotides as an FSHD therapeutic option.
Rights and Permissions
Citation: Mol Ther. 2016 Aug;24(8):1405-11. doi: 10.1038/mt.2016.111. Epub 2016 Jun 3. Link to article on publisher's site. This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Molecular therapy : the journal of the American Society of Gene Therapy
Chen, Jennifer C. J.; King, Oliver D.; Zhang, Yuanfan; Clayton, Nicholas P.; Spencer, Carrie; Wentworth, Bruce M.; Emerson, Charles P. Jr.; and Wagner, Kathryn R., "Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics" (2016). Cell and Developmental Biology Publications. 196.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.